1 Min Read
April 6 (Reuters) - Prescient Therapeutics Ltd
* Pre-specified success criteria of Phase 1B breast cancer trial have been met, and study will now progress to Phase 2. Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.